Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 44

1.

Efficient influenza A virus production in high cell density using the novel porcine suspension cell line PBG.PK2.1.

Gränicher G, Coronel J, Pralow A, Marichal-Gallardo P, Wolff M, Rapp E, Karlas A, Sandig V, Genzel Y, Reichl U.

Vaccine. 2019 Apr 17. pii: S0264-410X(19)30481-5. doi: 10.1016/j.vaccine.2019.04.030. [Epub ahead of print]

PMID:
31005427
2.

High titer MVA and influenza A virus production using a hybrid fed-batch/perfusion strategy with an ATF system.

Vázquez-Ramírez D, Jordan I, Sandig V, Genzel Y, Reichl U.

Appl Microbiol Biotechnol. 2019 Apr;103(7):3025-3035. doi: 10.1007/s00253-019-09694-2. Epub 2019 Feb 23.

3.

A Novel Chimeric Oncolytic Virus Vector for Improved Safety and Efficacy as a Platform for the Treatment of Hepatocellular Carcinoma.

Abdullahi S, Jäkel M, Behrend SJ, Steiger K, Topping G, Krabbe T, Colombo A, Sandig V, Schiergens TS, Thasler WE, Werner J, Lichtenthaler SF, Schmid RM, Ebert O, Altomonte J.

J Virol. 2018 Nov 12;92(23). pii: e01386-18. doi: 10.1128/JVI.01386-18. Print 2018 Dec 1.

4.

High-cell-density cultivations to increase MVA virus production.

Vázquez-Ramírez D, Genzel Y, Jordan I, Sandig V, Reichl U.

Vaccine. 2018 May 24;36(22):3124-3133. doi: 10.1016/j.vaccine.2017.10.112. Epub 2018 Feb 9.

PMID:
29433897
5.

In Vitro Evaluation of Glycoengineered RSV-F in the Human Artificial Lymph Node Reactor.

Radke L, Sandig G, Lubitz A, Schließer U, von Horsten HH, Blanchard V, Keil K, Sandig V, Giese C, Hummel M, Hinderlich S, Frohme M.

Bioengineering (Basel). 2017 Aug 15;4(3). pii: E70. doi: 10.3390/bioengineering4030070.

6.

Engineering of CHO Cells for the Production of Recombinant Glycoprotein Vaccines with Xylosylated N-glycans.

Sandig G, von Horsten HH, Radke L, Blanchard V, Frohme M, Giese C, Sandig V, Hinderlich S.

Bioengineering (Basel). 2017 Apr 28;4(2). pii: E38. doi: 10.3390/bioengineering4020038.

7.

Multi-level glyco-engineering techniques to generate IgG with defined Fc-glycans.

Dekkers G, Plomp R, Koeleman CA, Visser R, von Horsten HH, Sandig V, Rispens T, Wuhrer M, Vidarsson G.

Sci Rep. 2016 Nov 22;6:36964. doi: 10.1038/srep36964.

8.

Continuous cell lines from the Muscovy duck as potential replacement for primary cells in the production of avian vaccines.

Jordan I, John K, Höwing K, Lohr V, Penzes Z, Gubucz-Sombor E, Fu Y, Gao P, Harder T, Zádori Z, Sandig V.

Avian Pathol. 2016;45(2):137-55. doi: 10.1080/03079457.2016.1138280.

PMID:
26814192
9.

Applying Acylated Fucose Analogues to Metabolic Glycoengineering.

Rosenlöcher J, Böhrsch V, Sacharjat M, Blanchard V, Giese C, Sandig V, Hackenberger CPR, Hinderlich S.

Bioengineering (Basel). 2015 Nov 30;2(4):213-234. doi: 10.3390/bioengineering2040213.

10.

Rapid analysis of cell surface N-glycosylation from living cells using mass spectrometry.

Hamouda H, Kaup M, Ullah M, Berger M, Sandig V, Tauber R, Blanchard V.

J Proteome Res. 2014 Dec 5;13(12):6144-51. doi: 10.1021/pr5003005. Epub 2014 Nov 13.

PMID:
25348702
11.

Matrix and backstage: cellular substrates for viral vaccines.

Jordan I, Sandig V.

Viruses. 2014 Apr 11;6(4):1672-700. doi: 10.3390/v6041672. Review.

12.

The influence of cell growth and enzyme activity changes on intracellular metabolite dynamics in AGE1.HN.AAT cells.

Rath AG, Rehberg M, Janke R, Genzel Y, Scholz S, Noll T, Rose T, Sandig V, Reichl U.

J Biotechnol. 2014 May 20;178:43-53. doi: 10.1016/j.jbiotec.2014.03.012. Epub 2014 Mar 18.

PMID:
24657347
13.

Elements in the Development of a Production Process for Modified Vaccinia Virus Ankara.

Jordan I, Lohr V, Genzel Y, Reichl U, Sandig V.

Microorganisms. 2013 Nov 1;1(1):100-121. Review.

14.

Metabolism and metabolic burden by α1-antitrypsin production in human AGE1.HN cells.

Niklas J, Priesnitz C, Rose T, Sandig V, Heinzle E.

Metab Eng. 2013 Mar;16:103-14. doi: 10.1016/j.ymben.2013.01.002. Epub 2013 Feb 1.

PMID:
23376655
15.

A genotype of modified vaccinia Ankara (MVA) that facilitates replication in suspension cultures in chemically defined medium.

Jordan I, Horn D, John K, Sandig V.

Viruses. 2013 Jan 21;5(1):321-39. doi: 10.3390/v5010321.

16.

Live attenuated influenza viruses produced in a suspension process with avian AGE1.CR.pIX cells.

Lohr V, Genzel Y, Jordan I, Katinger D, Mahr S, Sandig V, Reichl U.

BMC Biotechnol. 2012 Oct 30;12:79. doi: 10.1186/1472-6750-12-79.

17.

Fucose-targeted glycoengineering of pharmaceutical cell lines.

Ogorek C, Jordan I, Sandig V, von Horsten HH.

Methods Mol Biol. 2012;907:507-17. doi: 10.1007/978-1-61779-974-7_29.

PMID:
22907371
18.

Authentication of the R06E fruit bat cell line.

Jordan I, Munster VJ, Sandig V.

Viruses. 2012 May;4(5):889-900. doi: 10.3390/v4050889. Epub 2012 May 23.

19.

Characterisation of cultivation of the human cell line AGE1.HN.AAT.

Schräder E, Scholz S, Niklas J, Rath A, Barradas OP, Jandt U, Sandig V, Rose T, Pörtner R, Reichl U, Zeng AP, Heinzle E, Noll T.

BMC Proc. 2011 Nov 22;5 Suppl 8:P87. doi: 10.1186/1753-6561-5-S8-P87. eCollection 2011. No abstract available.

20.

Physical methods for synchronization of a human production cell line.

Platas Barradas O, Jandt U, Hass R, Kasper C, Sandig V, Pörtner R, Zeng AP.

BMC Proc. 2011 Nov 22;5 Suppl 8:P49. doi: 10.1186/1753-6561-5-S8-P49. eCollection 2011. No abstract available.

Supplemental Content

Loading ...
Support Center